Alan Cabrera

Alan Cabrera

Auto-generated profile, based on publicly available information

Alan Cabrera

Department of Bioengineering, Rice University, Houston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Nature Methods
Verified
Journal Article
Open access
PDF file
BMBarun Mahata
Barun Mahata
ACAlan Cabrera
Alan Cabrera
DBDaniel A. Brenner
Daniel A. Brenner
RGRosa Selenia Guerra-Resendez
Rosa Selenia Guerra-Resendez
JLJing Li
Jing Li
IHIsaac B. Hilton
Isaac B. Hilton
Engineered transactivation domains (TADs) combined with programmable DNA binding platforms have revolutionized synthetic transcriptional control. Despite recent progress in programmable CRISPR–Cas-based transactivation (CRISPRa) technologies, the TADs used in these systems often contain poorly tolerated elements and/or are prohibitively large for many applications. Here, we defined and optimized minimal TADs built from human mechanosensitive transcription factors. We used these components to construct potent and compact multipartite transactivation modules (MSN, NMS and eN3x9) and to build the CRISPR–dCas9 recruited enhanced activation module (CRISPR-DREAM) platform. We found that CRISPR-DREAM was specific and robust across mammalian cell types, and efficiently stimulated transcription from diverse regulatory loci. We also showed that MSN and NMS were portable across Type I, II and V CRISPR systems, transcription activator-like effectors and zinc finger proteins. Further, as proofs of concept, we used dCas9-NMS to efficiently reprogram human fibroblasts into induced pluripotent stem cells and demonstrated that mechanosensitive transcription factor TADs are efficacious and well tolerated in therapeutically important primary human cell types. Finally, we leveraged the compact and potent features of these engineered TADs to build dual and all-in-one CRISPRa AAV systems. Altogether, these compact human TADs, fusion modules and delivery architectures should be valuable for synthetic transcriptional control in biomedical applications.

21 December 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FZFanglong Zhao
Fanglong Zhao
CSChunxiao Sun
Chunxiao Sun
ZLZhiwen Liu
Zhiwen Liu
ACAlan Cabrera
Alan Cabrera
MEMario Escobar
Mario Escobar
XGXue Gao
Xue Gao

21 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BMBarun Mahata
Barun Mahata
ACAlan Cabrera
Alan Cabrera
DBDaniel A. Brenner
Daniel A. Brenner
RGRosa Selenia Guerra-Resendez
Rosa Selenia Guerra-Resendez
JLJing Li
Jing Li
IHIsaac B. Hilton
Isaac B. Hilton
Engineered transactivation domains (TADs) combined with programmable DNA binding platforms have revolutionized synthetic transcriptional control. Despite recent progress in programmable CRISPR/Cas-based transactivation (CRISPRa) technologies, the TADs used in these systems often contain poorly tolerated elements and/or are prohibitively large for many applications. Here we defined and optimized minimal TADs built from human mechanosensitive transcription factors (MTFs). We used these components to construct potent and compact multipartite transactivation modules (MSN, NMS, and eN3×9) and to build the CRISPR- d Cas9 recruited e nhanced a ctivation m odule (CRISPR-DREAM) platform. We found that CRISPR-DREAM was specific, robust across mammalian cell types, and efficiently stimulated transcription from diverse regulatory loci. We also showed that MSN and NMS were portable across Type I, II, and V CRISPR systems, TALEs, and ZF proteins. Further, as proofs of concepts, we used dCas9-NMS to efficiently reprogram human fibroblasts into iPSCs and demonstrated that MTF TADs are efficacious and well tolerated in therapeutically important primary human cell types. Finally, we leveraged the compact and potent features of these engineered TADs to build new dual and all-in-one CRISPRa AAV systems. Altogether, these compact human TADs, fusion modules, and new delivery architectures should be valuable for synthetic transcriptional control in biomedical applications.